Introduction: Pancreatic cancer is one of the deadliest forms of cancer, and its diagnosis and effective treatment remain challenging. Utilizing omics approaches and data analysis can enhance our understanding of genetic mechanisms and aid in selecting appropriate chemotherapy drugs.
Methods: In this study, SNPs associated with pancreatic cancer were gathered from the NCBI database. For the analysis of polymorphisms and identification of genetically based side effects, the pharmacogenomic software MegaGen was employed.
Results: The findings indicated that three polymorphisms, rs28897753, rs1042522, rs1805794, and rs3027234, play a significant role in the development of pancreatic cancer. Additionally, the polymorphism rs63751221 was identified as having the greatest impact on the genetic side effects of chemotherapy drugs such as Alvoxal, Erloxha, and Oncozar.
Conclusion: The results underscore the importance of examining genetic polymorphisms in the diagnosis and effective treatment of pancreatic cancer. Identifying these variations can lead to the selection of drugs with fewer side effects and greater efficacy. Genetic testing prior to drug administration, especially for common genes like MLH1, is essential. By identifying polymorphisms, optimal treatments with minimal side effects can be chosen for patients.
Keywords: Polymorphisms, Pancreatic Cancer, Pharmacogenomics, Chemotherapy Side Effects, Data Analysis